What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study

被引:9
作者
Shim, Geumsook [1 ]
Park, Hye Youn [1 ]
Jang, Joon Hwan [1 ]
Kim, Euitae [1 ]
Park, Hye Yoon [1 ]
Hwang, Jae Yeon [1 ,2 ]
Kim, Sung Nyun [1 ]
Jang, Go-Eun [3 ]
Kwon, Jun Soo [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea
[2] Seoul Natl Univ, Brain & Cognit Sci WCU Program, Coll Nat Sci, Seoul 110744, South Korea
[3] SNU MRC, Clin Cognit Neurosci Ctr, Neurosci Inst, Seoul, South Korea
关键词
escitalopram; high dose; obsessive-compulsive disorder; selective serotonin reuptake inhibitors; SEROTONIN REUPTAKE INHIBITORS; POSITRON-EMISSION-TOMOGRAPHY; SOCIAL ANXIETY DISORDER; DOUBLE-BLIND; PREFRONTAL CORTEX; 20; MG; PLACEBO; PHARMACOTHERAPY; DOPAMINE; TRANSPORTER;
D O I
10.1097/YIC.0b013e32834a5c09
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study explored the efficacy and tolerability of very high doses (maximum dose of >40 mg/day), high doses (maximum dose of 25-40 mg/day), and standard doses (maximum dose of <= 20 mg/day) of escitalopram (ESC) as an anti-obsessive-compulsive disorder treatment in a naturalistic clinical setting. We reviewed the medical records of all patients with obsessive-compulsive disorder (n = 246) who had taken ESC between May 2006 and September 2009, and assigned Clinical Global Impression (CGI) scores, retrospectively. Of the total sample, 24.4, 38.2, and 37.4% patients received very high, high, and standard doses of ESC, and the mean daily maximum doses of ESC were 57.3 +/- 12. mg, 33.9 +/- 5.4 mg, and 13.4 +/- 5.8 mg, respectively. The CGI-Severity scores in each group decreased significantly after treatment with ESC, as evidenced by response rates (i.e. CGI-Improvement scores of 1 or 2) of 46.3, 43.2, and 26.2%, respectively. Although some adverse events increased in a dose-dependent manner, most could be managed with an ESC dose adjustment. These results imply that doses less than or equal to 40 mg/day ESC are sufficient for symptomatic improvement with good tolerability for most patients. Very high doses of ESC, on the other hand, can be considered for patients with inadequate therapeutic responses to the administration of 40 mg/day ESC. Int Clin Psychopharmacol 26:284-290 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 40 条
[1]   Response to high doses of citalopram in treatment-resistant obsessive-compulsive disorder [J].
Bejerot, S ;
Bodlund, O .
ACTA PSYCHIATRICA SCANDINAVICA, 1998, 98 (05) :423-424
[2]   Treatment of obsessive-compulsive disorder by US psychiatrists [J].
Blanco, Carlos ;
Olfson, Mark ;
Stein, Dan J. ;
Simpson, Helen Blair ;
Gameroff, Marc J. ;
Narrow, William H. .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (06) :946-951
[3]   Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses [J].
Blier, P ;
de Montigny, C .
BIOLOGICAL PSYCHIATRY, 1998, 44 (05) :313-323
[4]   Pharmacotherapies in the management of obsessive-compulsive disorder [J].
Blier, Pierre ;
Habib, Rami ;
Flament, Martine F. .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (07) :417-430
[5]   The activation of 5-HT2A receptors in prefrontal cortex enhances dopaminergic activity [J].
Bortolozzi, A ;
Díaz-Mataix, L ;
Scorza, MC ;
Celada, P ;
Artigas, F .
JOURNAL OF NEUROCHEMISTRY, 2005, 95 (06) :1597-1607
[6]  
Byerly MJ, 1996, AM J PSYCHIAT, V153, P1232
[7]   The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder [J].
Denys, D ;
van Megen, H ;
Westenberg, H .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (03) :109-114
[8]   Escitalopram - A review of its use in the management of anxiety disorders [J].
Dhillon, Sohita ;
Scott, Lesley J. ;
Plosker, Greg L. .
CNS DRUGS, 2006, 20 (09) :763-790
[9]   Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder [J].
Dougherty, Darin D. ;
Jameson, Mariko ;
Deckersbach, Thilo ;
Loh, Rebecca ;
Thompson-Hollands, Johanna ;
Jenike, Michael ;
Keuthen, Nancy J. .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2009, 24 (06) :306-311
[10]   Pharmacotherapy for obsessive-compulsive disorder [J].
Dougherty, DD ;
Rauch, SL ;
Jenike, MA .
JOURNAL OF CLINICAL PSYCHOLOGY, 2004, 60 (11) :1195-1202